These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 2966309

  • 1. D1- and D2-receptor antagonists induce catalepsy via different efferent striatal pathways [corrected].
    Ogren SO, Fuxe K.
    Neurosci Lett; 1988 Mar 10; 85(3):333-8. PubMed ID: 2966309
    [Abstract] [Full Text] [Related]

  • 2. Specific involvement of striatal D1 and D2 dopamine receptors in the neuroleptic catalepsy in rats.
    Wardas J, Pietraszek M, Ossowska K, Wolfarth S.
    Pol J Pharmacol; 1995 Mar 10; 47(4):349-53. PubMed ID: 8616516
    [Abstract] [Full Text] [Related]

  • 3. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O, Biggio G.
    Brain Res; 1990 Nov 12; 533(1):53-9. PubMed ID: 1982234
    [Abstract] [Full Text] [Related]

  • 4. Dopamine D1- and D2-dependent catalepsy in the rat requires functional NMDA receptors in the corpus striatum, nucleus accumbens and substantia nigra pars reticulata.
    Ozer H, Ekinci AC, Starr MS.
    Brain Res; 1997 Nov 28; 777(1-2):51-9. PubMed ID: 9449412
    [Abstract] [Full Text] [Related]

  • 5. The D2 dopamine receptor agonist LY171555 induces catalepsy in the mouse.
    Puglisi-Allegra S, Cabib S.
    Pharmacol Biochem Behav; 1988 Jul 28; 30(3):765-8. PubMed ID: 2974996
    [Abstract] [Full Text] [Related]

  • 6. In vivo assessment of release and metabolism of dopamine in the ventrolateral striatum of awake rats following administration of dopamine D1 and D2 receptor agonists and antagonists.
    See RE, Sorg BA, Chapman MA, Kalivas PW.
    Neuropharmacology; 1991 Dec 28; 30(12A):1269-74. PubMed ID: 1686300
    [Abstract] [Full Text] [Related]

  • 7. Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone.
    Protais P, Lesourd M, Comoy E.
    Eur J Pharmacol; 1998 Jul 10; 352(2-3):179-87. PubMed ID: 9716353
    [Abstract] [Full Text] [Related]

  • 8. Behavioral interactions between muscimol and compounds selective for the D1 and D2 dopamine receptor subtypes.
    Asin KE, Bednarz LM.
    Neurosci Lett; 1990 Jun 08; 113(3):286-91. PubMed ID: 2143274
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
    Breese GR, Criswell HE, McQuade RD, Iorio LC, Mueller RA.
    J Pharmacol Exp Ther; 1990 Feb 08; 252(2):558-67. PubMed ID: 1968972
    [Abstract] [Full Text] [Related]

  • 10. Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents.
    Protais P, Chagraoui A, Arbaoui J, Mocaër E.
    Eur J Pharmacol; 1994 Dec 12; 271(1):167-77. PubMed ID: 7698199
    [Abstract] [Full Text] [Related]

  • 11. In vivo release of [3H]gamma-aminobutyric acid in the rat neostriatum--II. Opposing effects of D1 and D2 dopamine receptor stimulation in the dorsal caudate putamen.
    Girault JA, Spampinato U, Glowinski J, Besson MJ.
    Neuroscience; 1986 Dec 12; 19(4):1109-17. PubMed ID: 2950336
    [Abstract] [Full Text] [Related]

  • 12. The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum.
    Anderson JJ, Randall S, Chase TN.
    J Pharmacol Exp Ther; 1995 Aug 12; 274(2):928-36. PubMed ID: 7636756
    [Abstract] [Full Text] [Related]

  • 13. Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy.
    Parashos SA, Marin C, Chase TN.
    Neurosci Lett; 1989 Oct 23; 105(1-2):169-73. PubMed ID: 2485878
    [Abstract] [Full Text] [Related]

  • 14. Evidence for striatal dopaminergic overactivity in paroxysmal dystonia indicated by microinjections in a genetic rodent model.
    Rehders JH, Löscher W, Richter A.
    Neuroscience; 2000 Oct 23; 97(2):267-77. PubMed ID: 10799758
    [Abstract] [Full Text] [Related]

  • 15. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ, Albers LJ, Le H, Creese I.
    J Pharmacol Exp Ther; 1986 Sep 23; 238(3):846-54. PubMed ID: 3018223
    [Abstract] [Full Text] [Related]

  • 16. Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists.
    Anderson JJ, Kask AM, Chase TN.
    Eur J Pharmacol; 1996 Jan 11; 295(2-3):163-8. PubMed ID: 8720580
    [Abstract] [Full Text] [Related]

  • 17. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J.
    Eur J Pharmacol; 1985 Jul 11; 113(1):79-88. PubMed ID: 2931283
    [Abstract] [Full Text] [Related]

  • 18. Opposing roles of dopamine D1 and D2 receptors in nigral gamma-[3H]aminobutyric acid release?
    Starr M.
    J Neurochem; 1987 Oct 11; 49(4):1042-9. PubMed ID: 2957468
    [Abstract] [Full Text] [Related]

  • 19. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA.
    J Pharmacol Exp Ther; 1987 Jan 11; 240(1):167-76. PubMed ID: 3100767
    [Abstract] [Full Text] [Related]

  • 20. Lateral hypothalamus-zona incerta region as an output station for the catalepsy induced by the blockade of striatal D1 and D2 dopamine receptors.
    Ossowska K, Wardas J, Golembiowska K, Wolfarth S.
    Brain Res; 1990 Jan 08; 506(2):311-5. PubMed ID: 2154287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.